强化治疗IDH突变AML中伴随基因突变的预后意义:ALFA研究
该研究回顾性分析319例接受强化化疗的初诊IDH突变AML患者,涵盖IDH1、IDH2R140和IDH2R172三个亚组。结果显示NPM1共突变是IDH1和IDH2R140亚组OS改善的预测因素,DNMT3A突变与IDH2R140亚组DFS缩短相关。非预后良好组中首次完全缓解期接受HSCT者OS和DFS更优。
要点
- IDH1突变AML中,NPM1共突变是OS改善的唯一独立预测因素(P<.0001)。
- IDH2R140突变中,正常核型和NPM1突变预测更好OS,DNMT3A突变与更短DFS相关。
- 非预后良好IDH1/2突变AML患者CR1期接受HSCT者OS和DFS显著更优。
核心结论
- 在强化化疗的IDH突变AML中,NPM1共突变状态是IDH1或IDH2R140亚组的主要预后因素。
- HSCT可改善非预后良好IDH1/2突变AML患者的OS,应充分整合入治疗策略。
研究设计与样本
- 回顾性分析3项ALFA前瞻性试验中319例初诊IDH突变AML患者,均接受强化化疗。
- IDH1突变127例,IDH2R140突变135例,IDH2R172突变57例。
主要发现
- IDH1突变组多因素分析中,NPM1突变是OS改善的唯一预测变量(P<.0001)。
- IDH2R140突变组中,正常核型(P=.008)和NPM1突变(P=.01)预测更好OS。
- IDH2R140组中NPM1突变与更好DFS相关(P=.0009),DNMT3A突变与更短DFS相关(P=.0006)。
- IDH2R172突变组多因素模型中,血小板计数是OS的唯一保留变量(P=.002)。
- 非预后良好ELN 2010 eligible患者中,71例(36%)在CR1期接受HSCT,OS(P=.03)和DFS(P=.02)均优于未移植者。
临床怎么用
- 初诊IDH突变AML强化化疗前应检测NPM1和DNMT3A共突变以细化预后分层。
- 非预后良好IDH1/2突变AML患者应考虑在CR1期进行HSCT以改善生存。
- 未来IDH抑制剂联合强化化疗的临床试验可考虑按NPM1突变状态进行分层。
局限性
- 本研究为回顾性分析,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with isocitrate dehydrogenase (IDH)-mutated acute myeloid leukemia (AML) treated by intensive chemotherapy (IC), prognostic significance of co-occurring genetic alterations and allogeneic hematopoietic stem cell transplantation (HSCT) are of particular interest with the advent of IDH1/2 mutant inhibitors. We retrospectively analyzed 319 patients with newly diagnosed AML (127 with IDH1, 135 with IDH2R140, and 57 with IDH2R172 mutations) treated with IC in 3 Acute Leukemia French Association prospective trials. In each IDH subgroup, we analyzed the prognostic impact of clinical and genetic covariates, and the role of HSCT. In patients with IDH1 mutations, the presence of NPM1 mutations was the only variable predicting improved overall survival (OS) in multivariate analysis (P < .0001). In IDH2R140-mutated AML, normal karyotype (P = .008) and NPM1 mutations (P = .01) predicted better OS. NPM1 mutations were associated with better disease-free survival (DFS; P = .0009), whereas the presence of DNMT3A mutations was associated with shorter DFS (P = .0006). In IDH2R172-mutated AML, platelet count was the only variable retained in the multivariate model for OS (P = .002). Among nonfavorable European LeukemiaNet 2010-eligible patients, 71 (36%) underwent HSCT in first complete remission (CR1) and had longer OS (P = .03) and DFS (P = .02) than nontransplanted patients. Future clinical trials testing frontline IDH inhibitors combined with IC may consider stratification on NPM1 mutational status, the primary prognostic factor in IDH1- or IDH2R140-mutated AML. HSCT improve OS of nonfavorable IDH1/2-mutated AML and should be fully integrated into the treatment strategy.
引用
- Duchmann M, Micol JB, Duployez N, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021. PMID: 33881523. doi:10.1182/blood.2020010165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。